

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Philip Ashton-Rickardt

Serial No.: 10/782,401

Filed: February 19, 2004

For: METHODS AND COMPOSITIONS FOR
THE INHIBITION OF CATHEPSINS

Group Art Unit: 1642

Examiner: Fetterolf, Brandon J.

Atty. Dkt. No.: ARCD:390US

Confirmation No.: 4307

CERTIFICATE OF ELECTRONIC SUBMISSION

DATE OF SUBMISSION: January 24, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. § 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/ARCD:390US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Monica A. De La Paz
Reg. No. 54,662
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: January 24, 2007

Form PTO-1449 (modified)		Atty. Docket No. ARCD:390US	Serial No. 10/782,401
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Philip Ashton-Rickardt	
		Filing Date: February 19, 2004	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C21	Borrow <i>et al.</i> , "Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression," <i>J. Virol.</i> , 69:1059-1070, 1995.
	C22	Ciurea <i>et al.</i> , "Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice," <i>Proc. Natl. Acad. Sci. USA</i> , 96:11964-11969, 1999.
	C23	Evans <i>et al.</i> , "Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease," <i>J. Exp. Med.</i> , 184:2371-2384, 1996.
	C24	Hotchin, "The biology of lymphocytic choriomeningitis infection: virus-induced immune disease," <i>Cold Spring Harbor Symp. Quant Biol.</i> , 27:479-499, 1962.
	C25	Jaeckel <i>et al.</i> , "Viruses and Diabetes," <i>Annals of the NY Acad. Sci.</i> , 958:7-25, 2002.
	C26	Kagi <i>et al.</i> , "Development of insulinitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity," <i>J. Exp. Med.</i> , 183:2143-2152, 1996.
	C27	Khanolkar <i>et al.</i> , "T cell responses to viral infections: lessons from lymphocytic choriomeningitis virus," <i>Immunol. Res.</i> , 26:309-321, 2002.
	C28	Klenerman and Zinkernagel, "What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus?," <i>Immunological Reviews</i> , 159:5-16, 1997.

25732655.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. ARCD:390US	Serial No. 10/782,401
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Philip Ashton-Rickardt	
		Filing Date: February 19, 2004	Group: 1642
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-2	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C29	Ludewig <i>et al.</i> , "Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease," <i>J. Exp. Med.</i> , 191:795-804, 2000.
	C30	Nansen and Thomsen, "Viral infection causes rapid sensitization to lipopolysaccharide: central role of IFN-alpha beta," <i>J. Immunol.</i> , 166:982-988, 2001.
	C31	Odermatt <i>et al.</i> , "Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8252-8256, 1991.
	C32	Ohashi <i>et al.</i> , "Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and tumor necrosis factor-alpha," <i>J. Immunol.</i> , 150:5185-5194, 1993.
	C33	Oldstone, "Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunologic injury--two sides of the same coin," <i>Prog. Med. Virol.</i> , 19:84-119, 1975.
	C34	Stellrecht-Broomhall, "Evidence for immune-mediated destruction as mechanism for LCMV-induced anemia in persistently infected mice," <i>Viral Immunol.</i> , 4:269-280, 1991.
	C35	Zinkernagel <i>et al.</i> , "Susceptibility to murine lymphocytic choriomeningitis maps to class I MHC genes- a model for MHC/disease associations," <i>Nature</i> , 316:814-817, 1985.
	C36	Zinkernagel <i>et al.</i> , "T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay?," <i>J. Exp. Med.</i> , 164:1075-1092, 1986.
	C37	Zinkernagel, "Immunity, immunopathology and vaccines against HIV?," <i>Vaccine</i> , 20:1913-1917, 2002.

25732655.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.